Logo image of PULM

PULMATRIX INC (PULM) Stock Fundamental Analysis

NASDAQ:PULM - Nasdaq - US74584P3010 - Common Stock - Currency: USD

7  +0.05 (+0.72%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PULM. PULM was compared to 195 industry peers in the Pharmaceuticals industry. While PULM has a great health rating, there are worries on its profitability. While showing a medium growth rate, PULM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PULM has reported negative net income.
In the past year PULM has reported a negative cash flow from operations.
PULM had negative earnings in each of the past 5 years.
In the past 5 years PULM always reported negative operating cash flow.
PULM Yearly Net Income VS EBIT VS OCF VS FCFPULM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

The Return On Assets of PULM (-151.43%) is worse than 84.10% of its industry peers.
The Return On Equity of PULM (-170.59%) is worse than 65.13% of its industry peers.
Industry RankSector Rank
ROA -151.43%
ROE -170.59%
ROIC N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
PULM Yearly ROA, ROE, ROICPULM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PULM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PULM Yearly Profit, Operating, Gross MarginsPULM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PULM remains at a similar level compared to 1 year ago.
Compared to 5 years ago, PULM has more shares outstanding
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PULM Yearly Shares OutstandingPULM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PULM Yearly Total Debt VS Total AssetsPULM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -37.72, we must say that PULM is in the distress zone and has some risk of bankruptcy.
PULM has a Altman-Z score of -37.72. This is amonst the worse of the industry: PULM underperforms 87.69% of its industry peers.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.72
ROIC/WACCN/A
WACC9.75%
PULM Yearly LT Debt VS Equity VS FCFPULM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

PULM has a Current Ratio of 8.90. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
PULM has a Current ratio of 8.90. This is amongst the best in the industry. PULM outperforms 81.03% of its industry peers.
PULM has a Quick Ratio of 8.90. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
PULM has a better Quick ratio (8.90) than 81.03% of its industry peers.
Industry RankSector Rank
Current Ratio 8.9
Quick Ratio 8.9
PULM Yearly Current Assets VS Current LiabilitesPULM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for PULM have decreased strongly by -38.26% in the last year.
PULM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -83.55%.
The Revenue has been decreasing by -0.26% on average over the past years.
EPS 1Y (TTM)-38.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.12%
Revenue 1Y (TTM)-83.55%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PULM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.43% on average per year.
Based on estimates for the next years, PULM will show a very strong growth in Revenue. The Revenue will grow by 43.66% on average per year.
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PULM Yearly Revenue VS EstimatesPULM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PULM Yearly EPS VS EstimatesPULM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PULM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PULM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PULM Price Earnings VS Forward Price EarningsPULM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PULM Per share dataPULM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as PULM's earnings are expected to grow with 28.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.57%
EPS Next 3Y28.64%

More info and screens

0

5. Dividend

5.1 Amount

PULM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMATRIX INC

NASDAQ:PULM (6/27/2025, 8:00:00 PM)

7

+0.05 (+0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-09 2025-05-09
Earnings (Next)08-11 2025-08-11
Inst Owners8.81%
Inst Owner Change-2.42%
Ins Owners0.66%
Ins Owner Change0%
Market Cap25.55M
Analysts82.86
Price TargetN/A
Short Float %0.6%
Short Ratio1.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.3
P/FCF N/A
P/OCF N/A
P/B 3.57
P/tB 3.57
EV/EBITDA N/A
EPS(TTM)-3.34
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-2.75
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS0.53
BVpS1.96
TBVpS1.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -151.43%
ROE -170.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.89%
Cap/Sales 12.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.9
Quick Ratio 8.9
Altman-Z -37.72
F-Score3
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)64.52%
Cap/Depr(5y)80.64%
Cap/Sales(3y)5.28%
Cap/Sales(5y)4.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.12%
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue 1Y (TTM)-83.55%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-100%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%
EBIT growth 1Y-3.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.95%
OCF growth 3YN/A
OCF growth 5YN/A